Drug
Xanomeline And Trospium Chloride
Xanomeline And Trospium Chloride: highest development phase Phase 3, developed by Karuna Therapeutics. 9 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Karuna Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Xanomeline and Trospium Chloride Capsules NCT04659174 | Phase 3 | Schizophrenia |
| Xanomeline and Trospium Chloride Capsules NCT04820309 | Phase 3 | Schizophrenia |
| Xanomeline and Trospium Chloride Capsules NCT04659161 | Phase 3 | Schizophrenia |
| Xanomeline and Trospium Chloride Capsules NCT04738123 | Phase 3 | Schizophrenia |
| Xanomeline and Trospium Chloride Capsules NCT05919823 | Phase 3 | Schizophrenia |
| Xanomeline and Trospium Chloride Capsules NCT05304767 | Phase 3 | Schizophrenia |
| Xanomeline and Trospium Chloride Capsules NCT05145413 | Phase 3 | Schizophrenia |
| Xanomeline and Trospium Chloride Capsules NCT05643170 | Phase 3 | Schizophrenia |
| Xanomeline and Trospium Chloride Capsules NCT03697252 | Phase 2 | Schizophrenia |
Latest
No recent events.
Follow Xanomeline And Trospium Chloride on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.